2006-2007 Annual Report on the Development of China's Bio-Pharmaceutical Industry

II. Overview of China's Bio-Pharmaceutical Industry, 2005-2006
(I) Development Environment
1. Policy Environment
2. Investment Environment
3. Market Environment
4. Information Service Environment

(II) Present Situation
1. Industry Size
2. Molecular Biological Materials
3. Pharmaceutical Materials
4. Biological Equipment and Methods
5. Biological Evolution and Ecological Materials
6. Plant Materials
7. Animal Materials

(III) Characteristics
1. New technology becomes main conventional methods in the development of bio-pharmaceuticals
2. Bio-pharmaceutical enterprises engaged in closer cooperation, with finer division of work
3. The high-end R&D of new products dramatically boosts the industry's competitiveness
4. Outsourcing becomes bio-pharmaceutical enterprises' important development strategy

(IV) Existing Problems
1. Low Industrialization Degree, Long Product Cycle
2. Low Innovation Degree, Lack of Key Technology
3. Loose Market Regulation, Decreased Product Credit

(V) Industry Segments
1. Genetic Engineering Drugs
2. Antibody Engineering Pharmaceutics
3. Blood Products
4. Vaccines
5. Diagnosis Reagents
6. Biochips
7. Chemical Medicine
8. Traditional Chinese Medicine

III. Analysis of the Industry Chain of China's Bio-Pharmaceutical Industry in 2006
(I) Structure of Industry Chain
1. Technology Platform
2. Research & Development
3. Clinical Drugs
4. Translating Research Results into Products
5. Channels

(II) Present Situation of Supply & Demand in the Industry Chain
(III) Characteristics of the Industry Chain & Problems
1. Basic technology platforms are completed but underutilized
2. Cross-regional transfer of product technology is brisk but somewhat blind
3. Despite strong R&D capability, the loss of R&D results is alarming

IV. Analysis of the Competitiveness of China's Bio-Pharmaceutical Industry in 2006
(I) Competition Model
1. Product Price
2. Brand Competition
3. Channel Competition
4. Technical Competition

(II) Competition Situation
1. Overall Competition Situation
2. Potential Entrants and Substitute Products
3. Distribution of Leading Brands

(III) Leading Brands' Strategies
1. Tiantan Biological
2. Novo Nordisk
3. ...

V. Development Trend of China's Bio-Pharmaceutical Industry, 2007-2009
(I) Impetuses
1. Policy Factors
2. Economic Factors
3. Social Factors
4. Technical Factors

(II) Development Trend
1. Trend of Production and Consumption
2. Development Trend of Products
3. Trend of Technological Innovation
4. Trend of Competition

VI. Forecast of China's Bio-Pharmaceutical Industry, 2007-2009
(I) Analysis of Development Potential
(II) Forecast of Development
1. Forecast of Size
2. Forecast of Structure

VII. Investment Opportunities in China's Bio-Pharmaceutical Industry, 2007-2009
(I) Index System
(II) Investment Opportunities

VIII. Recommendations from CCID Consulting.
(I) Strategic Recommendations
(II) Investment Recommendations

List of Tables
Size of China's Bio-Pharmaceutical Market, 2005-2006
Size of China's Genetic Engineering Drugs Market in 2006
Size of China's Antibody Engineering Pharmaceutics Market in 2006
Size of China's Blood Products Market in 2006
Size of China's Vaccine Market in 2006
Size of China's Biochip Market in 2006

List of Figures
Size of the Global Bio-Pharmaceutical Market, 2006-2007
Development of the U.S.A Bio-Pharmaceutical Market, 2006-2007
Development of the European Bio-Pharmaceutical Market, 2006-2007
Development of the Danish Bio-Pharmaceutical Market, 2006-2007
Development of Singapore's Bio-Pharmaceutical Market, 2006-2007